

Temporary benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Apo-Folic Acid 5 mg Tablet (DIN 00426849) manufactured by Apotex Inc. and Euro Folic 5 mg Tablet (DIN 02285673) manufactured by Euro-Pharm, Jamp-Folic Acid 5 mg Tablet (DIN 02366061) manufactured by Jamp Pharma Corporation will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of February 24, 2016, all claims for Jamp-Folic Acid 5 mg Tablet (DIN 02366061) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Due to the unavailability of Apo-Linezolid 600 mg Tablet (DIN 02426552) manufactured by Apotex Inc., Sandoz Linezolid 600 mg Tablet (DIN 02422689) manufactured by Sandoz Canada Inc and Zyvoxam 600 mg Tablet (DIN 02243684) manufactured by Pfizer Canada Inc., Zyvoxam 20 mg/ml Oral Suspension (DIN 02243686), manufactured by Pfizer Canada Inc. will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of February 24, 2016, all claims for Zyvoxam 20 mg/ml Oral Suspension (DIN 02243686) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Due to the unavailability of Ratio-Morphine 5 mg/ml Oral Syrup (DIN 00607770) manufactured by Ratiopharm, Doloral 5 mg/ml Oral Syrup (DIN 00614505) manufactured by Atlas Laboratories Inc. will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of March 2, 2016, all claims for Doloral 5 mg/ml Oral Syrup (DIN 00614505) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

... continued from previous page

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC that the shortage of Mylan-Cimetidine 600 mg Tablet (DIN 02227460) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **April 1, 2016**.

CIMETIDINE

600 MG TABLET

00002227460	MYLAN-CIMETIDINE	MYP	\$ 0.1702
00000600067	APO-CIMETIDINE	APX	\$ 0.3405

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Brimonidine 0.2% Ophthalmic Solution (DIN 02260077) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **April 4, 2016**.

BRIMONIDINE TARTRATE

0.2 % OPHTHALMIC SOLUTION

00002260077	APO-BRIMONIDINE	APX	\$ 1.1550
00002246284	PMS-BRIMONIDINE	PMS	\$ 1.1550
00002305429	SANDOZ BRIMONIDINE	SDZ	\$ 1.1550
00002236876	ALPHAGAN	ALL	\$ 3.3800

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC that the shortage of Mylan-Verapamil SR 120 mg Tablet (DIN 02210347) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **April 4, 2016**.

VERAPAMIL HCL

120 MG SUSTAINED-RELEASE TABLET

00002246893	APO-VERAP SR	APX	\$ 0.5078
00002210347	MYLAN-VERAPAMIL SR	MYP	\$ 0.5078
00001907123	ISOPTIN SR	BGP	\$ 1.4035

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.589 2016/03

